Clinical benefit of Hylan GF-20 over conventional therapy at similar cost in knee OA .
Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis
Joint Bone Spine. 2003 Aug;70(4):276-81506 patients with knee osteoarthritis and failed response to pharmacological intervention were randomized to receive either three weekly intra-articular injections of Hylan G-F 20 (Synvisc) or conventional therapy. The purpose of the study was to compare the clinical efficacy of the two treatment regimens over a span of 9 months, as well as to evaluate economic factors associated with Hylan G-F 20 treatment. The results indicated significant improvements in clinical outcomes in the patients receiving Hylan G-F 20 in comparison to conventional treatment. Both medical and total costs were similar between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
